NeoVac
1 known investors
NeoVac develops mRNA therapeutics using lipid nanoparticles designed for improved safety, flexibility, and precision. The company reports early human study results and is building a platform for next-generation therapeutic and preventative vaccines.
Investors · 1
Companies House · registry record
View on Companies House ↗- Registered name
- NEOVAC LTD
- Company number
- 13606487
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 7 Sept 2021
- Registered office
- Suites 1 And 2 127 Olympic Avenue, Milton Park, Abingdon, OX14 4SA
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology
- Accounts
- last made up to 31 Dec 2024 · next due 30 Sept 2026
- Confirmation statement
- last made up to 30 Mar 2026 · next due 13 Apr 2027
Current officers · 10
- Tova Sharon — secretary, appointed 2 Dec 2021
- Eran Eilat — director, appointed 7 Sept 2021
- Halil Emecen — director, appointed 7 Sept 2021
- Heinrich Haas — director, appointed 19 Aug 2025
- Douglas Hansen-Luke — director, appointed 7 Sept 2021
- Adrian Hill — director, appointed 7 Sept 2021
- Suzana Nahum Zilberberg — director, appointed 13 Jan 2023
- Dan Peer — director, appointed 7 Sept 2021
- Martin Wodak — director, appointed 10 Apr 2024
- Aleš Štrancar — director, appointed 28 Jan 2026
Source: Companies House public register · retrieved 23 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
Frequently asked questions
- What does NeoVac do?
- NeoVac develops mRNA therapeutics using lipid nanoparticles designed for improved safety, flexibility, and precision. The company reports early human study results and is building a platform for next-generation therapeutic and preventative vaccines.
- Who are NeoVac's investors?
- NeoVac's investors include Future Planet Capital.